The Zhitong Finance App learned that AstraZeneca (AZN.US) announced on Friday that its SERENA-4 phase III trial for first-line treatment of ER-positive and HER2-negative advanced breast cancer with oral selective estrogen receptor (SERD) Etcamah (camizestrant) combined with pabosinib did not reach the main end. Although there was a numerical improvement in the patients' progression-free survival (PFS), it was not statistically significant.

The Zhitong Finance App learned that AstraZeneca (AZN.US) announced on Friday that its SERENA-4 phase III trial for first-line treatment of ER-positive and HER2-negative advanced breast cancer with oral selective estrogen receptor (SERD) Etcamah (camizestrant) combined with pabosinib did not reach the main end. Although there was a numerical improvement in the patients' progression-free survival (PFS), it was not statistically significant.